CONMED Corporation (NYSE:CNMD ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Patrick J. Beyer - President, CEO & Director Todd W.
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $0.98 per share a year ago.
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CONMED Corporation (NYSE:CNMD ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Pat Beyer - Chief Executive Officer and President Todd Garner - Executive Vice President and Chief Financial Officer Conference Call Participants Matt O'Brien - Piper Sandler Robbie Marcus - JPMorgan Rick Wise - Stifel Young Li - Jefferies Travis Steed - Bank of America Mike Matson - Needham Operator Good day, and thank you for standing by. Welcome to CONMED's First Quarter Fiscal 2025 Earnings Conference Call.
While the top- and bottom-line numbers for Conmed (CNMD) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Conmed (CNMD) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.79 per share a year ago.
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.